1. Home
  2. CCSI vs DSGN Comparison

CCSI vs DSGN Comparison

Compare CCSI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consensus Cloud Solutions Inc.

CCSI

Consensus Cloud Solutions Inc.

HOLD

Current Price

$23.73

Market Cap

549.8M

Sector

Technology

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.11

Market Cap

528.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCSI
DSGN
Founded
2021
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
549.8M
528.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CCSI
DSGN
Price
$23.73
$9.11
Analyst Decision
Hold
Buy
Analyst Count
3
2
Target Price
$29.00
$13.50
AVG Volume (30 Days)
173.2K
335.0K
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.22
N/A
Revenue
$349,609,000.00
N/A
Revenue This Year
$1.67
N/A
Revenue Next Year
$0.97
N/A
P/E Ratio
$5.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.84
$2.60
52 Week High
$32.10
$10.31

Technical Indicators

Market Signals
Indicator
CCSI
DSGN
Relative Strength Index (RSI) 52.73 57.87
Support Level $21.92 $9.00
Resistance Level $23.14 $9.67
Average True Range (ATR) 0.79 0.67
MACD 0.39 -0.08
Stochastic Oscillator 83.79 46.28

Price Performance

Historical Comparison
CCSI
DSGN

About CCSI Consensus Cloud Solutions Inc.

Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: